Clinical Trial Update: Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder [Phase 4]

View source ↗

Summary

Phase 4 clinical trial sponsored by Novartis evaluated darifenacin with behavioral therapy for symptoms of overactive bladder and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• Darifenacin (darifenacin)

Snippet

Sponsor: Novartis | Conditions: Urinary Incontinence | Phase 4 | Status: COMPLETED